24/7 Market News Snapshot 23 January, 2025 – Tiziana Life Sciences Ltd. Common Shares (NASDAQ:TLSA)

January 23, 2025

DENVER, Colo., 23 January, 2025 (247marketnews.com) – (NASDAQ:TLSA) are discussed in this article.
The trading activity of Tiziana Life Sciences Ltd. (TLSA) has garnered attention, with shares opening at $0.80 and currently trading at $0.813, reflecting a 2.02% increase from the previous close of $0.797. The robust trading volume of nearly 8 million shares suggests strong market interest. From a technical standpoint, TLSA appears to be experiencing bullish momentum, breaching its prior closing price, which could signal further upward movement if buying pressure maintains. Investors should keep an eye on resistance levels surpassing $0.813 while also considering key support around $0.797 to evaluate optimal entry or exit strategies in this fluctuating environment.

Adding to the company’s positive sentiment, Tiziana Life Sciences has announced encouraging preclinical results regarding its investigational treatment for traumatic spinal cord injury (SCI) utilizing intranasal foralumab, a novel human anti-CD3 monoclonal antibody. This therapeutic candidate is engineered to target the inflammation linked to SCI, a condition that profoundly impacts patients’ mobility and quality of life.

Preliminary studies indicate that the nasal application of anti-CD3 significantly enhances motor function and reduces harmful microglial activation, which is crucial in SCI pathology. Dr. Howard Weiner, the Chairman of Tiziana’s Scientific Advisory Board, highlighted the importance of these findings in reducing inflammation associated with spinal cord injuries. Dr. Saef Izzy, an Associate Professor of Neurology, also noted the treatment’s ability to improve motor outputs in affected models.

Ivor Elrifi, CEO of Tiziana Life Sciences, articulated the company’s ambition to expand the application of their innovative foralumab technology from existing treatments for multiple sclerosis to addressing critical needs in spinal cord injury. With an estimated 300,000 individuals living with SCI in the U.S. and 17,000 new cases annually, this breakthrough positions Tiziana as a promising player in advancing effective therapeutic solutions for debilitating conditions.

Related news for (TLSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.